CurrentCareSourcePolicy N/A

Rytelo (imetelstat) — Coverage Criteria for Lower‑Risk Myelodysplastic Syndromes

Defines prior authorization, coverage criteria, dosing, and prescribing requirements for Rytelo (imetelstat IV) for adults with lower‑risk myelodysplastic syndrome (MDS) with transfusion‑dependent anemia for the CareSource population in North Carolina.

Policy Summary

PayerCareSource

PolicyRytelo (imetelstat) — Coverage Criteria for Lower‑Risk MDS

Policy CodePolicy N/A

Change TypeNCCN guidance added

Effective DateN/A

Next Review DateN/A

Key ActionSubmit prior authorization with documentation of age ≥18, transfusion‑dependent anemia (≥4 RBC units/8 weeks), absence of del(5q), prior ESA trial or ineligibility, and specialist involvement.

SourceLink

POLICY UPDATE CHANGES

Overview updated with NCCN Myelodysplastic Syndromes guidelines (version 3.2024 July 25, 2024) including recommendations for Rytelo.

7.1 mg/kgrecommended dose per infusion

q4wrecommended dosing interval

≥4 RBC/8wtransfusion‑dependent definition

del(5q)cytogenetic exclusion

6 monthsinitial authorization

Coverage Criteria for Rytelo (imetelstat)

Initial Therapy

Covered when the following are met for FDA-approved indication (MDS):

Overall requirements: Patient is >= 18 years of age; diagnosis of low- to intermediate-1 risk myelodysplastic syndrome (MDS) per IPSS; transfusion-dependent anemia defined as requiring >= 4 red blood cell units over an 8-week period; does NOT have deletion 5q [del(5q)] cytogenetic abnormality; patient has not responded to, lost response to, or is ineligible for erythropoiesis-stimulating agents (ESAs); Rytelo will NOT be used in combination with an ESA; medication is prescribed by or in consultation with an oncologist or hematologist.

Approve initial therapy for 6 months; dosing up to 7.1 mg/kg IV every 4 weeks.

Continuation Therapy

Continuation/Current therapy:

Maintenance approval: Patient currently receiving Rytelo: approve for 1 year if the prescriber documents a clinically meaningful decrease in transfusion burden.

If patient has not completed 6 months (24 weeks) of therapy or is restarting, use initial therapy criteria.

Policy Summary

PayerCareSource

PolicyRytelo (imetelstat) — Coverage Criteria for Lower‑Risk MDS

Policy CodePolicy N/A

Change TypeNCCN guidance added

Effective DateN/A

Next Review DateN/A

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Rytelo was not studied in patients with deletion 5q (del(5q)) cytogenetic abnormality; therefore, coverage is not recommended for patients with del(5q). The policy requires documentation that the patient does NOT have del(5q) as part of meeting the initial therapy criteria and before approval is recommended.

Per the prescribing guidance, therapy should be discontinued if a patient does not experience a decrease in red blood cell transfusion burden after 24 weeks (6 doses) or if unacceptable toxicity occurs; this discontinuation guidance applies regardless of cytogenetic status and reinforces that del(5q) must be excluded prior to initiating Rytelo.

Use of Rytelo outside the circumstances listed in the Recommended Authorization Criteria is not recommended for approval. Requests that do not meet the documented initial or continuation criteria should not be approved.

The criteria set defines the covered population (adult patients with lower‑risk MDS, transfusion‑dependent anemia, without del(5q), prior ESA nonresponse/ineligibility, appropriate prescribing specialist, and dosing up to 7.1 mg/kg every 4 weeks); deviations from these requirements lack supporting evidence in the policy and are therefore not recommended.

Regimen	Dose	Route	Frequency / Infusion time	Indication / Notes
Imetelstat (Rytelo)
7.1 mg/kg
Intravenous (IV)
Every 4 weeks; infusion administered over 2 hours
Transfusion-dependent anemia in lower-risk myelodysplastic syndromes (MDS) without del(5q) after failure of or ineligibility for ESAs; approve initial therapy for 6 months per criteria; do not combine with ESAs

Billing and Coding

Codes referencedmixed

N/A	No specific CPT/HCPCS/ICD codes listed in this policy document.

inv-06: Transfusion burden

Transfusion burden threshold>= 4 red blood cell (RBC) units over an 8-week period

ContextDefines transfusion-dependent anemia used in initial therapy authorization (Initial Therapy criterion iii)

Authorization implicationRequired to meet ‘Initial Therapy’ coverage criteria for approval of Rytelo

inv-07: Ring sideroblasts threshold

Ring sideroblasts (RS+) threshold>= 15% ring sideroblasts defines RS+

RS- definition (comparative)RS- when ring sideroblasts < 15%

Clinical useUsed to categorize patients per NCCN guidance for treatment sequencing (RS+ vs RS-)

Provider Requirements and Actions

Prior Authorization

Prior Authorization Required

Prior Authorization is required for medical-benefit coverage of Rytelo. Approval is recommended only for requests that meet the policy Criteria and Dosing for the FDA‑approved indication. Extended approvals are allowed if the patient continues to meet the Criteria and Dosing. Requests for doses outside the established dosing in this policy will be considered case-by-case by a clinician (e.g., Medical Director or Pharmacist). All approvals are provided for the duration noted in the policy. Rytelo must be prescribed by or in consultation with a physician who specializes in the condition treated (oncologist or hematologist).

Prior authorization required before initiation
Requests outside documented dosing considered case-by-case
Prescriber requirement: oncologist or hematologist

Step Therapy

Step Therapy Relationships

Step therapy relationships: Rytelo is positioned relative to erythropoiesis‑stimulating agents (ESAs) and luspatercept (Reblozyl) according to NCCN‑based guidance. For RS- patients with serum erythropoietin < 500 mU/mL, Rytelo is recommended following no response to ESAs (epoetin alfa products or darbepoetin alfa). For RS+ patients, Rytelo is recommended following no response to Reblozyl when serum erythropoietin < 500 mU/mL, and is listed as an alternative or recommended following no response to Reblozyl when erythropoietin ≥ 500 mU/mL. When applicable, Rytelo may be used as initial therapy for certain RS+ patients per guideline categorizations — however prior authorization review will confirm appropriate positioning relative to ESA and luspatercept therapy.

RS- with EPO < 500 mU/mL: trial of ESAs (e.g., epoetin alfa products or Aranesp) required before Rytelo
RS+ patients: Rytelo generally after no response to Reblozyl (luspatercept); use/sequence varies by serum EPO level
Authorization review will verify prior therapies (ESA and/or luspatercept) were tried or were inappropriate/ineligible

Documentation Required

Required Clinical Documentation

Required clinical documentation must be submitted with the authorization request to support medical necessity and dosing. Incomplete documentation may delay or result in denial of the request.

Patient age (must be ≥ 18 years)
Diagnosis of low‑ to intermediate‑1 risk MDS with method used to determine risk (e.g., IPSS)
Sideroblast status (RS+ defined as ≥15% ring sideroblasts; RS- defined as <15% or <5% with SF3B1 mutation) and serum erythropoietin (EPO) level
Transfusion history (e.g., transfusion‑dependent anemia defined as ≥4 RBC units over an 8‑week period) and documentation of clinically meaningful decrease in transfusion burden if requesting continuation
Prior therapy history documenting lack of response, loss of response, intolerance, or ineligibility to ESAs and/or luspatercept (Reblozyl) as applicable
Confirmation patient does NOT have del(5q) cytogenetic abnormality
Planned dosing and route (review will confirm dosing up to 7.1 mg/kg IV every 4 weeks or justify off‑label dosing), and prescriber specialty (oncology/hematology)
If restarting therapy or with <6 months prior therapy, submission should reference Initial Therapy criteria

Denial Risk

Denial Triggers

Requests that do not meet the policy's Recommended Authorization Criteria, lack required documentation, or seek use in situations listed as not recommended will generally be denied.

Denial likely if patient does not meet age, MDS risk category, transfusion dependence, absence of del(5q), prior therapy requirements, or dosing criteria
Denial likely for indications or circumstances explicitly listed as Not Recommended for Approval
Requests for doses outside established dosing without clinician justification may be denied

Definitions and Biomarker Criteria

inv-13: Definition of transfusion-dependent anemia

DefinitionTransfusion-dependent anemia: requiring transfusion of >= 4 red blood cell units over an 8-week period

Use in policyThis definition is applied as part of the Initial Therapy coverage criteria for Rytelo

Clinical consequencePatients meeting this threshold may be eligible for initial 6-month approval if other criteria are met

inv-14: RS+ / RS- definitions

RS+ definitionSideroblast positive (RS+) when ring sideroblasts >= 15%

RS- definitionSideroblast negative (RS-) when ring sideroblasts < 15%

SF3B1 considerationPatients with ring sideroblasts <5% with an SF3B1 mutation are categorized as RS- per guidance text

inv-16: SF3B1 / ring sideroblasts biomarker requirement

Primary biomarker thresholdRS+ defined by ring sideroblasts >= 15% (use this threshold to determine RS status)

SF3B1 modifierRing sideroblasts <5% with an SF3B1 mutation may be considered RS- (guidance text)

Policy applicationRS status and SF3B1 results inform step-therapy recommendations and when Rytelo is recommended relative to luspatercept per NCCN guidance

Line of Therapy Placement

second-line | first-line (selected RS+ scenarios)

Line of therapy: Rytelo is used after failure of erythropoiesis-stimulating agents (ESAs) and, for RS+ patients, after no response to luspatercept (Reblozyl) depending on serum erythropoietin level per NCCN; may be recommended as initial therapy in selected RS+ patients with serum erythropoietin >= 500 mU/mL per NCCN guidance.

Consistent with NCCN categories referenced in document.

Background

Rytelo (imetelstat) is an oligonucleotide telomerase inhibitor indicated for treatment of transfusion‑dependent anemia in lower‑risk myelodysplastic syndromes (MDS) for patients who have not responded to, have lost response to, or are ineligible for erythropoiesis‑stimulating agents (ESAs).

The policy-aligned FDA dosing guidance is 7.1 mg/kg IV administered over 2 hours every 4 weeks, with approval recommendations provided for an initial duration of 6 months when initial criteria are met and for continuation (up to one year) only if the prescriber documents a clinically meaningful decrease in transfusion burden. Therapy should be discontinued if no decrease in transfusion burden is seen after 24 weeks (6 doses) or if unacceptable toxicity occurs.

Covered Regimens and Dosing

Agent	Dose per infusion	Administration	Interval	Authorization notes
Imetelstat (Rytelo)
7.1 mg/kg
IV infusion over 2 hours
Once every 4 weeks (not more frequently than every 4 weeks)
Initial approval: up to 6 months when patient meets coverage criteria; continuation: approve 1 year if clinically meaningful decrease in transfusion burden; do not use in combination with ESAs; prescribed by or in consultation with an oncologist/hematologist